All in the chart ... If it bounce back up from $7.06 area then it can move higher to $9 area where it will meet resistance of the price control line of that value zone .P.S. A can be wrong ,there are few days to find out .
Komentar:
On March 3, the company released interim results from its clinical trials, which showed that the vaccine was 81% effective against COVID-19. What likely got investors even more bullish was news that it also showed "significant immunogenicity against the rapidly emerging variants."
The vaccine showed a higher rate of effectiveness than the COVID-19 vaccine from Johnson & Johnson, which has received an EUA and is just 66% effective (both Moderna and Pfizer have efficacy rates of more than 90%). And again, Ocugen's stock rose as much as 46% during the day, while a trading volume of 181 million soared to more than 10 times the previous day's levels.
In February, Bharat secured a deal to supply the Brazilian Health Ministry with 20 million doses of its vaccine, worth approximately $290 million. That averages out to a price of $14.50 per dose. If Bharat can produce 700 million doses of the vaccine by the end of the year, that could generate more than $10 billion in sales -- if it sells all of them at that average price.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
The vaccine showed a higher rate of effectiveness than the COVID-19 vaccine from Johnson & Johnson, which has received an EUA and is just 66% effective (both Moderna and Pfizer have efficacy rates of more than 90%). And again, Ocugen's stock rose as much as 46% during the day, while a trading volume of 181 million soared to more than 10 times the previous day's levels.
In February, Bharat secured a deal to supply the Brazilian Health Ministry with 20 million doses of its vaccine, worth approximately $290 million. That averages out to a price of $14.50 per dose. If Bharat can produce 700 million doses of the vaccine by the end of the year, that could generate more than $10 billion in sales -- if it sells all of them at that average price.